6CM
MCRB icon

683 Capital Management’s Seres Therapeutics MCRB Stock Holding History

683 Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,314
Closed -$778K – 253
2025
Q4 		$778K Buy
+52,314
New +$912K 0.03% 161

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

683 Capital Management's MCRB Position: Q1 2026 in Review

683 Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 52,314 shares — an estimated $778K sold.

683 Capital Management first reported a position in MCRB in Q4 2025 and held it in 1 quarter. The position peaked at $778K in Q4 2025. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • 683 Capital Management reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
  • 683 Capital Management sold 52,314 Seres Therapeutics shares in Q1 2026, an estimated $778K.
  • 683 Capital Management first reported a position in Seres Therapeutics in Q4 2025 and held it in 1 quarter.
  • 683 Capital Management's Seres Therapeutics position peaked at $778K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.